GlassScriptPhysician profile
Tyson C Parker
NPI 1295921484
$9,620.01
in general payments reported to CMS, 2019-2025
66 companies · $1,794 in 2025
The $1,794 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,922 · 2022: $2,161 · 2023: $1,747 · 2024: $1,995 · 2025: $1,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,531 · Education: $6.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,530.52 |
| Education | $6.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,434.57 | 2021-2025 | |
| Lilly USA, LLC | $758.18 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $420.81 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.74 | 2021-2025 | Jardiance, Synjardy |
| Amgen INC. | $369.92 | 2021-2025 | Prolia, Evenity, Repatha |
| Astellas Pharma US INC | $350.89 | 2021-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $333.68 | 2021-2025 | Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $327.01 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $318.81 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $293.65 | 2024-2025 | Fanapt |
| Glaxosmithkline, LLC. | $256.74 | 2021-2025 | Trelegy Ellipta |
| Antares Pharma, INC. | $234.03 | 2021-2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $202.99 | 2022-2023 | |
| Lundbeck LLC | $160.19 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $159.89 | 2021-2025 | Ajovy, Austedo Xr |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyson Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.